What Vyome Therapeutics does

Vyome Holdings, Inc. (Nasdaq: HIND), operating through its Vyome Therapeutics subsidiaries, is a clinical-stage specialty pharmaceutical company developing novel therapies for immuno-inflammatory and rare diseases with significant unmet medical need. The company is headquartered in Cambridge, Massachusetts, with R&D operations in Delhi, India, and operates a US-India innovation corridor model designed for capital-efficient drug development. Its core pipeline comprises three clinical-stage assets: VT-1953, a topical gel for Malignant Fungating Wounds (MFW) with orphan drug designation potential and a 75% malodor reduction observed in Phase 2; VT-1908, a non-steroidal IMPDH-targeting ophthalmic drop for uveitis that matched steroid efficacy in preclinical models; and VB-1953, a dual-action (DNA gyrase + TLR-MD2) topical for antibiotic-resistant inflammatory acne with safety data across 550+ patients.

The company's commercial revenue is derived from a licensing and marketing agreement with Sun Pharma covering reformulated topical anti-fungal products (including Luliconazole) in India, generating royalties and milestone payments. Vyome also commercializes its Molecular Replacement Therapeutics (MRT) technology platform through this partnership. The company completed a reverse merger with ReShape Lifesciences in August 2025 to become publicly listed on Nasdaq, raised capital via a concurrent private placement of approximately $7.3 million, and established a $12 million ATM facility with Maxim Group. In September 2025, Vyome acquired MIT AI startup Oculo, Inc. to build a new AI-in-healthcare business unit targeting systemic inflammation, and in May 2026 in-licensed preclinical JAK inhibitor assets from Impetis Biosciences (a TATA Enterprise). The company is positioning itself as a three-pillar healthcare platform spanning biotech, medical devices, and AI.

Name

Vyome Therapeutics

Legal name

Vyome Holdings, Inc.

Website

https://vyometx.com

Company type

Public

Founded year

2010

Operating status

Operating

Headcount range

11–50 employees

Short description

Vyome Therapeutics is a clinical-stage specialty pharmaceutical company developing immuno-inflammatory therapies (VT-1953, VT-1908, VB-1953) via a US-India innovation corridor, targeting patients with malignant fungating wounds, uveitis, and drug-resistant acne, and generating royalty revenue from anti-fungal products licensed to Sun Pharma in India.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Immunology & Inflammation Pharmaceuticals (HLAIAAAD)

akta.pro secondary industries

Ophthalmology Specialty Pharmaceuticals (HLAIACAK), Rare Immunology, Autoimmune & Autoinflammatory Therapies (HLAIAIAE), Infectious Disease Specialty Pharmaceuticals (Non-vaccine) (HLAIACAM)

Keywords

• Immuno-inflammatory therapeutics
• Clinical-stage pharmaceuticals
• Topical drug development
• Anti-fungal formulations
• Rare disease therapies

Headquarters

HQ city

Delhi

HQ country

India

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Product Sales (Pharmaceutical Segment): Revenue from sale of reformulated topical anti-fungal products commercialized in India. Products manufactured by third parties and sold through Sun Pharma partnership.
2. Royalties and Milestone Payments: Royalty income and milestone payments from Sun Pharma licensing agreement for Luliconazole anti-fungal product. Royalties linked to net sales value of products sold by Sun Pharma to third parties. Development and sales-based milestones earned upon completion of performance obligations.
3. Future Product Revenue (Biotechnology Segment): Pre-revenue biotechnology segment developing clinical-stage drug candidates. Will generate revenue upon FDA approval and commercialization of VT-1953, VT-1908, and VB-1953 programs.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Vyome Holdings is a clinical-stage specialty pharmaceutical company developing novel therapies for immuno-inflammatory diseases, with three lead programs: VT-1953 (topical gel for malignant fungating wounds), VT-1908 (non-steroidal eye drops for uveitis), and VB-1953 (treatment for antibiotic-resistant acne). The company also generates revenue through Sun Pharma licensing of its commercialized topical anti-fungal products (Luliconazole) in India and operates an MRT technology platform.

Product overview

Vyome Holdings is a Cambridge, MA-based clinical-stage specialty pharmaceutical company with a US-India innovation corridor operating model. The company is building a 3-pillar platform combining Biotech & Pharma, Medical Devices, and AI in Healthcare. The core product pipeline includes VT-1953 (Malignant Fungating Wounds treatment), VT-1908 (Uveitis eye drops), and VB-1953 (Drug-Resistant Acne treatment), all targeting immuno-inflammatory diseases. The company has commercialized anti-fungal products using its MRT technology platform through Sun Pharma licensing agreements in India. Following the merger with ReShape Lifesciences (completed August 2025), Vyome trades on Nasdaq under ticker HIND and is advancing its clinical-stage assets through regulatory discussions.

Differentiator

Problem solved

Functional benefit

Brands

• VT-1953: Lead clinical program - novel topical gel for treatment of malignant fungating wounds (MFW), a potentially orphan drug designated program.
• VT-1908
• VB-1953

Products and services

• VT-1953

Quantifiable outcome

• 75% reduction in malodor early efficacy analysis for VT-1953
• +3 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered core and minor.

• Oculo, Inc.coreStrategic or Co-development Partner · 29 September 2025Acquired MIT AI startup Oculo, Inc. to launch a new business unit focused on using AI to address inflammation. Plans include developing an AI psychiatrist to diagnose and treat systemic inflammation, targeting behavioral drivers and biomarkers.
• ReShape LifesciencescoreStrategic or Co-development Partner · 10 July 2024Merger agreement combining Vyome Therapeutics with ReShape Lifesciences in an all-stock transaction. Completed August 15, 2025. Combined company renamed Vyome Holdings, Inc. focused on immuno-inflammatory assets and US-India opportunities. ReShape sold most assets to Biorad Medisys for $5.16 million in cash.
• Biorad MedisysminorOthers · 10 July 2024Asset purchase agreement where ReShape Lifesciences sold substantially all assets to Biorad Medisys for $5.16 million in cash (later adjusted to $2.25 million). Transaction completed July 8, 2025.
• Sun PharmacoreOEM/ Whitelabel/ Licensing Partner · 1 December 2020Licensing and marketing agreement with Sun Pharma group of companies for topical anti-fungal products in India. Includes reformulated anti-fungal shampoo and Luliconazole cream. Vyome receives royalties, milestone payments, and net service fee payments based on Sun Pharma's product sales. The Luliconazole agreement was commercialized in 2023.

Scale indicators7 records

Recent moves8 records

Expansion highlights5 records

Direct peers

• Arcutis Biotherapeutics: Clinical-stage dermatology specialty pharma with FDA-approved Zoryve and a pipeline targeting inflammatory skin conditions including acne and atopic dermatitis. Directly comparable to Vyome as a small-cap US dermatology/inflammation biotech pursuing topical therapies with novel mechanisms.
• Aldeyra Therapeutics: Clinical-stage biotech developing novel therapies for immune-mediated ocular and systemic diseases, with a primary focus on non-steroidal treatments for ocular inflammation (uveitis, dry eye). Highly comparable to Vyome's VT-1908 program targeting uveitis with IMPDH inhibition.
• Aclaris Therapeutics: Specialty pharmaceutical company focused on immuno-inflammatory dermatology, developing novel topical and systemic therapies for conditions including acne and other inflammatory skin diseases. Comparable clinical-stage US biotech with similar inflammatory derm focus as Vyome.
• Cassiopea (acquired by Sun Pharma): Specialty dermatology company that developed Winlevi (clascoterone) for acne vulgaris, a topical first-in-class therapy. Direct acne competitor and notably was acquired by Sun Pharma — Vyome's own Indian commercial partner.
• Aurinia Pharmaceuticals: Specialty pharma developing voclosporin for autoimmune diseases including lupus nephritis. Comparable clinical/specialty pharma model targeting immune-mediated conditions, with similar size and capital structure dynamics to Vyome.
• Dermavant Sciences: Dermatology-focused subsidiary of Roivant Sciences developing topical therapies for inflammatory skin conditions including psoriasis and atopic dermatitis. Comparable specialty pharma focused on immuno-inflammatory derm indications similar to Vyome's pipeline.

Emerging players

• Tarsier Pharma: Emerging ophthalmology biotech developing TRS01 and other non-steroidal therapies for uveitis and other inflammatory eye diseases. Direct competitor to Vyome's VT-1908 uveitis program with similar steroid-sparing approach.

Broad incumbents

• Amgen (Horizon Therapeutics): Large biopharmaceutical company that acquired Horizon Therapeutics in 2023, gaining Tepezza and other specialty inflammation/immunology assets. Represents the broad incumbent landscape in immuno-inflammatory diseases that Vyome's niche programs compete against for physician mindshare and commercial resources.

Others

• Sun Pharmaceutical Industries: Vyome's licensing and commercial partner for anti-fungal products in India. Also a strategic comparable in dermatology and specialty pharma in emerging markets, and a potential acquirer given its prior dermatology M&A (e.g., Cassiopea).
• Maravai LifeSciences: Life sciences tools and services company with nucleic acid and biologics manufacturing capabilities used by clinical-stage biotechs including those developing inflammatory disease therapies. Tangentially comparable as a small-cap public biotech adjacent to Vyome's clinical development supply chain.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/vyomebio
• Facebookfacebook.com/vyomebio
• LinkedInlinkedin.com/company/vyome-biosciences

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries4 records

Funding overview

Funding rounds8 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vyome Therapeutics